Greenwich Lifesciences Cost Of Revenue Over Time
| GLSI Stock | USD 11.61 0.60 4.91% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Greenwich Lifesciences Performance and Greenwich Lifesciences Correlation. Greenwich |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Cost Of Revenue Analysis
Compare Greenwich Lifesciences and related stocks such as Reviva Pharmaceuticals, Eyenovia, and Immutep Ltd ADR Cost Of Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RVPH | 724.7 K | 724.7 K | 724.7 K | 724.7 K | 724.7 K | 724.7 K | 724.7 K | 724.7 K | 724.7 K | 724.7 K | 724.7 K | 724.7 K | 724.7 K | 724.7 K | 652.3 K | 579.8 K |
| EYEN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 15.3 K | 800 K | 1.6 M | 307.4 K | 3.8 K | 4.4 K | 4.1 K |
| IMMP | 117.2 K | 117.2 K | 939.1 K | 713.3 K | 219.1 K | 7.1 M | 1.7 M | 10 M | 16.6 M | 22.5 M | 2.1 M | 2.1 M | 2.1 M | 41.5 M | 47.8 M | 50.2 M |
| AVXL | 3 K | 12 K | 12 K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| MNOV | 437.6 K | 0.0 | 11.7 M | 10 M | 0.0 | 26.7 K | 14.1 K | 28.1 K | 25.9 K | 23.9 K | 21.3 K | 212.4 K | 212.4 K | 20.3 K | 18.3 K | 17.4 K |
| NXTC | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 19.8 M | 34.2 K | 46.6 K | 4.3 M | 4.5 M | 3.7 M | 3.3 M | 3.7 M |
| ENTX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 210 K | 209 K | 373 K | 101 K | 56 K | 64.4 K | 116 K |
| XFOR | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 672 K | 1.9 M | 1.9 M | 2 M | 2 M | 2.3 M | 2.4 M |
| TERN | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 195 K | 394 K | 512 K | 1 M | 881 K | 1 M | 564.5 K |
| DAWN | 155 K | 155 K | 155 K | 155 K | 155 K | 155 K | 155 K | 155 K | 155 K | 155 K | 155 K | 199 K | 531 K | 383 K | 5.3 M | 5.5 M |
| PDSB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 98.4 K | 98.4 K | 176.3 K | 246.4 K | 49.1 K | 57.3 K | 65.9 K | 98.6 K |
| INZY | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 217 K | 1.1 M | 1.2 M | 1.3 M | 1.5 M | 841.1 K |
| ABOS | 8.6 K | 8.6 K | 8.6 K | 8.6 K | 8.6 K | 8.6 K | 8.6 K | 8.6 K | 8.6 K | 8.6 K | 8 K | 4 K | 169 K | 42.3 M | 48.7 M | 51.1 M |
Greenwich Lifesciences and related stocks such as Reviva Pharmaceuticals, Eyenovia, and Immutep Ltd ADR Cost Of Revenue description
Cost of Revenue is found on Greenwich Lifesciences income statement and represents the costs associated with goods and services Greenwich Lifesciences provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.My Equities
My Current Equities and Potential Positions
| Greenwich Lifesciences | GLSI |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Texas; U.S.A |
| Exchange | NASDAQ Exchange |
USD 11.61
Check out Greenwich Lifesciences Performance and Greenwich Lifesciences Correlation. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Greenwich Lifesciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.